Mo1374 – 12 Years of Prospective Pancreatic Cancer Surveillance: Results of the Dutch Nationwide Program in High-Risk Individuals

Published on May 1, 2019in Gastroenterology17.373
· DOI :10.1016/S0016-5085(19)38826-2
Kasper A. Overbeek3
Estimated H-index: 3
Iris J. M. Levink2
Estimated H-index: 2
+ 13 AuthorsMarco J. Bruno67
Estimated H-index: 67
📖 Papers frequently viewed together
1 Author (Christine Ko)
Cited By2
#1Randa G. Hanna‐Sawires (LUMC: Leiden University Medical Center)H-Index: 1
Last. Rob A. E. M. TollenaarH-Index: 71
view all 9 authors...
Pancreatic ductal adenocarcinoma (PDAC) is known as a highly aggressive malignant disease. Prognosis for patients is notoriously poor, despite improvements in surgical techniques and new (neo)adjuvant chemotherapy regimens. Early detection of PDAC may increase the overall survival. It is furthermore foreseen that precision medicine will provide improved prognostic stratification and prediction of therapeutic response. In this review, omics-based discovery efforts are presented that aim for novel...
#1Gabriele Capurso (UniSR: Vita-Salute San Raffaele University)H-Index: 56
#2Salvatore Paiella (University of Verona)H-Index: 23
Last. Massimo FalconiH-Index: 105
view all 8 authors...
Abstract Pancreatic cancer is one of the main causes of cancer-related death worldwide, with a survival rate around 9%. In Italy 13,500 new cases of pancreatic cancer occurred in 2019. It is estimated that at least 5% have a hereditary background. Surveillance is advisable for healthy individuals with specific genetic syndromes with or without family history of pancreatic cancer or members of families with multiple cases of pancreatic cancer, irrespective of genetic syndromes. In 2010 the Italia...